Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329168 | 0.77 | MAPT (0.47) | RAB9ANPC1TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3641590 | 0.74 | PTGS2 (0.40) | CYP3A4CYP2C9 | |
| SCHEMBL1110277 | 0.72 | RAB9A (0.47) | RAB9ANPC1TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL8649626 | 0.68 | CALM1 (0.48) | CALM1RAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL2614741 | 0.68 | CALM1 (0.61) | CALM1RAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL15323022 | 0.68 | CALM1 (0.61) | CALM1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL8652020 | 0.67 | CALM1 (0.41) | CALM1RAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL2163588 | 0.66 | CALM1 (0.50) | CALM1L3MBTL1ALDH1A1TSHRTAAR1 | |
| SCHEMBL1110129 | 0.65 | CALM1 (0.44) | CALM1RAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL460058 | 0.64 | CALM1 (0.55) | CALM1RAB9ANPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102006-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2018-06-07 | — | — | WO | claimed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | claimed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | claimed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| WO-2000071572-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-4558058-A | HYPOTENSIVE AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1985-12-10 | — | — | US | claimed |
| EP-0116708-A1 | Substituted 1,4-dihydropyridines, method for their preparation and their use as pharmaceuticals | CASSELLA Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | claimed |
| WO-2018102006-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-2616458-B1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS II | BASF SE (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-20130203821-A1 | Pyridine Compounds for Controlling Invertebrate Pests II | BASF SE (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2616458-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS II | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034960-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS II | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-4681891-A | Dihydro-2,6-dimethyl pyridines, formulations and method of use for treating angina pectoris, high blood pressure or disturbances of cerebral or peripheral blood flow | CASSELLA AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
| EP-0183091-A2 | 1,4-Dihydropyridines, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1986-06-04 | — | — | EP | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0172509-A2 | Process for the preparation of optically active, substituted 1,4-dihydropyridines and their use as medicaments | CASSELLA Aktiengesellschaft (DE) | 1986-02-26 | — | — | EP | disclosed |
| US-4558058-A | HYPOTENSIVE AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1985-12-10 | — | — | US | disclosed |
| EP-0116708-A1 | Substituted 1,4-dihydropyridines, method for their preparation and their use as pharmaceuticals | CASSELLA Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203821-A1 | Pyridine Compounds for Controlling Invertebrate Pests II | GRIN2A, NR2C2, GRIA2 | CALM1 2010/4885RAB9A 977/4885NPC1 3632/4885 |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | CALM1 3031/4885RAB9A 2091/4885NPC1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.